EA-2353

About Endogena Therapeutics

Endogena Therapeutics is a private, clinical-stage biotechnology company based in Basel, Switzerland, founded in 2013. The company has developed a proprietary drug discovery platform aimed at identifying small molecules that can stimulate endogenous tissue repair by selectively regulating adult stem and progenitor cells. Its most advanced program is a Phase I/IIa clinical trial for retinitis pigmentosa (RP), which has received FDA Orphan Drug Designation and Fast Track status, with preliminary efficacy data presented in 2024. The pipeline also includes preclinical programs for geographic atrophy (dry AMD) and idiopathic pulmonary fibrosis (IPF).

Therapeutic Areas

Other Retinitis Pigmentosa Drugs